Mela Sciences (NSDQ:MELA) announced an expanded 3-year manufacturing contract with long-time supplier Askion GmbH for production of the MelaFind devices.
MelaFind, the company’s flagship product, is a handheld, non-invasive melanoma detection and identification system designed to help a physician decide whether or not to biopsy a suspect patch of skin.
Commercial launch of the MelaFind system is set to begin in the U.S. during the first quarter of 2012, according to a press release. The company will also begin penetrating European markets, starting with Germany.
Mela won FDA clearance for the MelaFind system in Nov. 2011 after more than 2 years, 2 panel reviews and 1 citizens’ petitions worth of effort.
The years-long plight made Mela Sciences a poster child for charges of unpredictability at the FDA, culminating in a Progressive Policy Institute report asking "Is the FDA Strangling Innovation?"
MelaFind won CE Mark approval in the European Union in September.
MELA shares were up 3 percent at the end of the day today, closing at $4.55.
Here’s a roundup of companies announcing new distribution deals and other joint ventures.
Calgary Scientific inks deal with Dell
Calgary Scientific Inc. inked a deal with Dell (NSDQ:DELL) to enhance mobility and add advanced web-enabled visualization to Dell’s Unified Clinical Archive solution. Read more
MTF, ConMed in allograft deal
The Musculoskeletal Transplant Foundation agreed to a deal that will see ConMed’s (NSDQ:CNMD) Linvatec subsidiary distribute its sports medicine allograft tissues and Cascade platelet-rich plasma. Read more
GE Healthcare, Biosense Webster in co-distribution pact
GE Healthcare inked a long-term agreement with Biosense Webster to co-distribute their electrophysiology systems. Read more
Austin Bioinnovation spins out 1st firm
The Austen BioInnovation Institute in Akron, Ohio, spun out its first startup company, APTO Orthopaedics, which is developing a non-invasive spinal fixation system for children with scoliosis. Read more
Bioject explores "strategic alternatives"
Bioject Medical Technologies (OTC:BJCT) hired Snehal Patel to help it explore the proverbial "strategic alternatives," including a sale of the company. Read more